Vericel Co. (NASDAQ:VCEL - Get Free Report) CEO Dominick Colangelo sold 24,850 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $41.89, for a total transaction of $1,040,966.50. Following the transaction, the chief executive officer now owns 260,354 shares in the company, valued at $10,906,229.06. This represents a 8.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Dominick Colangelo also recently made the following trade(s):
- On Thursday, March 13th, Dominick Colangelo sold 26,592 shares of Vericel stock. The shares were sold at an average price of $45.78, for a total value of $1,217,381.76.
Vericel Price Performance
Shares of VCEL stock opened at $41.25 on Friday. The firm has a 50-day moving average of $49.21 and a 200-day moving average of $51.42. Vericel Co. has a one year low of $37.76 and a one year high of $63.00. The company has a market cap of $2.07 billion, a P/E ratio of 687.61 and a beta of 1.61.
Institutional Investors Weigh In On Vericel
Several institutional investors and hedge funds have recently added to or reduced their stakes in VCEL. Wellington Management Group LLP increased its position in shares of Vericel by 214.0% during the 3rd quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company's stock valued at $24,837,000 after purchasing an additional 400,667 shares during the last quarter. Stifel Financial Corp increased its holdings in Vericel by 40.0% during the third quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company's stock worth $1,186,000 after buying an additional 8,020 shares during the last quarter. Geode Capital Management LLC increased its holdings in Vericel by 0.8% during the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company's stock worth $48,768,000 after buying an additional 9,613 shares during the last quarter. Louisiana State Employees Retirement System raised its position in Vericel by 0.8% in the fourth quarter. Louisiana State Employees Retirement System now owns 23,900 shares of the biotechnology company's stock worth $1,312,000 after acquiring an additional 200 shares during the period. Finally, Park Avenue Securities LLC purchased a new position in Vericel in the fourth quarter valued at about $280,000.
Wall Street Analyst Weigh In
VCEL has been the topic of several recent research reports. Stephens reiterated an "overweight" rating and issued a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Vericel in a report on Friday, February 28th. StockNews.com upgraded shares of Vericel from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Finally, Truist Financial lowered their target price on shares of Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a report on Friday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Vericel currently has a consensus rating of "Moderate Buy" and a consensus price target of $60.86.
Read Our Latest Report on VCEL
Vericel Company Profile
(
Get Free Report)
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
